

# pUNO1-hSTING-M155

Expression vector containing M155 isoform human STING (V155M) open reading frame

Catalog code: puno1-hsting-m155

<https://www.invivogen.com/hsting-m155>

For research use only

Version 19K10-MM

## PRODUCT INFORMATION

### Contents

- 20 µg of lyophilized plasmid DNA
- 2 x 1 ml blasticidin at 10 mg/ml

### Storage and Stability

- Product is shipped at room temperature.
- Lyophilized DNA should be stored at -20°C.
- Resuspended DNA should be stored at -20°C and is stable at least for 1 year.
- Store blasticidin at 4°C or -20°C.\*

\*The expiry date is specified on the product label.

### Quality control

- Plasmid construct has been confirmed by restriction analysis and full-length open reading frame (ORF) sequencing.
- Plasmid DNA was purified by ion exchange chromatography.

## GENERAL PRODUCT USE

• **Subclone gene into another vector.** Two unique restriction sites flank the gene, allowing convenient excision. The 5' site is BspEI which is compatible with AgeI, XmaI, NgoMIV and SgrAI. The 3' site is NheI which is compatible with XbaI, SpeI, and AvrII.

• **Stable gene expression in mammalian cells.** pUNO1 plasmids can be used directly in transfection experiments both *in vitro* and *in vivo*. pUNO1 plasmids contain the blasticidin-resistance gene (*bsr*) driven by the CMV promoter/enhancer in tandem with the bacterial EM7 promoter. This allows the amplification of the plasmid in *E. coli*, as well as the selection of stable clones in mammalian cells using the same selective antibiotic. pUNO1 allows high levels of expression and secretion of the gene product.

## METHODS

### Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile water. Store resuspended plasmid at -20°C.

### Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or other commonly used laboratory *E. coli* strains, such as DH5α.

### Blasticidin usage

Blasticidin should be used at 25-100 µg/ml in bacteria and 1-30 µg/ml in mammalian cells. Blasticidin is supplied at 10 mg/ml in HEPES buffer.

## PLASMID FEATURES

• **Bsr (blasticidin resistance gene):** The *bsr* gene from *Bacillus cereus* encodes a deaminase that confers resistance to the antibiotic blasticidin. The *bsr* gene is driven by the CMV promoter/enhancer in tandem with the bacterial EM7 promoter. Therefore, blasticidin can be used to select stable mammalian cells transfectedants and *E. coli* transformants.

• **CMV promoter & enhancer** drives the expression of the blasticidin resistance in mammalian cells.

### • Human STING-M155

**ORF size:** 1140 bp

**Cloning fragment size:** 1181 bp

STING (stimulator of interferon genes; also known as TMEM173, MITA, MPYS, and ERIS) is essential for the interferon (IFN) response to microbial or self-DNA, and acts as a direct sensor of cyclic dinucleotides (CDNs). Several variants of STING have been described in the human population. The M155 (V155M) variant results in a gain-of-function mutation with the constitutive activation of STING and an upregulation of IFN production<sup>1</sup>. This mutation is associated with a chronic autoinflammatory disease, known as STING-associated vasculopathy with onset in infancy (SAVI)<sup>2</sup>.

• **EF-1 $\alpha$ /HTLV hybrid promoter** is a composite promoter comprised of the Elongation Factor-1 $\alpha$  (EF-1 $\alpha$ ) core promoter<sup>3</sup> and the 5' untranslated region of the Human T-Cell Leukemia Virus (HTLV). EF-1 $\alpha$  utilizes a type 2 promoter that encodes for a «house keeping» gene. It is expressed at high levels in all cell cycles and lower levels during G0 phase. The promoter is also non-tissue specific; it is highly expressed in all cell types. The R segment and part of the U5 sequence (R-U5') of the HTLV Type 1 Long Terminal Repeat<sup>4</sup> has been coupled to the EF-1 $\alpha$  promoter to enhance stability of DNA and RNA. This modification not only increases steady state transcription, but also significantly increases translation efficiency possibly through mRNA stabilization.

• **SV40 pAn:** The Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions, resulting in high levels of steady-state mRNAs<sup>5</sup>.

• **pMB1 ori** is a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.

• **Human beta-Globin polyA** is a strong polyadenylation (pAn) signal placed downstream of *bsr*. The use of beta-globin pAn minimizes interference<sup>6</sup> and possible recombination events with the SV40 polyadenylation signal.

1. Jeremiah N. et al., 2013. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. *J Clin Invest.* 124(12):5516-20.

2. Liu Y. et al., 2014. Activated STING in a vascular and pulmonary syndrome. *N Engl J Med.* 371(6):507-18.

3. Kim D. et al., 1990. Use of the human elongation factor 1 $\alpha$  promoter as a versatile and efficient expression system. *Gene.* 91(2):217-23.

4. Takebe Y. et al., 1988. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. *Mol Cell Biol.* 8(1):466-72.

5. Carswell S. & Alwine J., 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. *Mol Cell Biol.* 9(10):4248-58.

6. Yu J. & Russell J., 2001. Structural and functional analysis of an mRNP complex that mediates the high stability of human  $\beta$ -globin mRNA. *Mol Cell Biol.* 21(17):5879-88.

## RELATED PRODUCTS

Product	Description	Cat. Code
Blasticidin ChemiComp GT116	Selection antibiotic Competent <i>E. coli</i>	ant-bl-1 gt116-11

## TECHNICAL SUPPORT


InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong : +852 3622-3480

E-mail: info@invivogen.com



**PvuI (7)**

1 GGATCTCGCATCGCTCCGGTCCCCGTCAAGGGCAGAGCGCACATGCCACAGTCCCCGAGAAGTTGGGGGA

---

MfeI (82)

75 GGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGGGGTAAACTGGAAAGTGTGCTGTACTGGCT

---

**Psp1406I (203)**

149 CGGCCTTTCCCAGGGTGGGGAGAACCGTATATAAGTCAGTAGTCGCCGTGACGTTCTTCGCAACG

---

**HindIII (245)**

223 GTTTGCCAGAACACAGCTGAAGCTCGAGGGGCTCGCATCTCCTCACGCCCGCCGCTACCTGA

**Bsu36I (291)**

297 GGCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCTCCGCCTGTGGTGCCTCTGAAC TGCGTCCGCCGT

---

**NgoMIV (441)**

**NgoMI (441)**

**NaeI (441)**

371 CTAGGTAAGTTAAAGCTCAGGTGAGACCGGGCTTGTCGGCGCTCCCTGGAGCCTACCTAGACTCAGCC

---

445 GGCTCTCACGCTTGCCCTGACCTGCTCAACTCTACGTCTTGTTCGTTCTGCGCCGTTAC

---

**SphI (566)**

519 AGATCCAAGCTGTGACCGGCCCTACCTGAGATCACCGGCTCGGACAGCATGCCCACTCCAGCCTGCATCCA

→ 1 M P H S S L H P

Bsp120I (617)

593 TCCATCCGTGTCGCCAGGGTACGGGGCCAGAAGGCAGCCTGGTCTGCTGAGTGCCTGCCGGTACCC

9 S I P C P R G H G A Q K A A L V L L S A C L V T L

Asp718I (701)

667 TTGGGGCTAGGAGAGCCACCAGAGCACACTCTCGGTACCTGGTCTCCACCTAGCCTCCCTGCAGCTGGAC

33 W G L G E P P E H T L R Y L V L H L A S L Q L G

Asp718I (794)

741 TGCTGTTAACGGGGCTGCAGCCTGGCTGAGGAGCTGCGCCACATCCACTCCAGGTACGGGGCAGCTACTGG

58 L L L N G V C S L A E E L R H I H S R Y R G S Y W

Bsp120I (854)

815 AGGACTGTGCGGCCCTGCCTGGCTGCCCTCCGGTGGGGCCCTGTTGCTGCTGTCCATCTATTCTACTA

83 R T V R A C L G C P L R R G A L L L L S I Y F Y Y

889 CTCCCTCCCAAATGCGGTGGCCGCCCTCACTTGGATGCTGCCCTCTGGGCCCTCGCAGGCCTGAACA

107 S L P N A V G P P F T W M L A L L G L S Q A L N

**SfiI (970)**

**BglIII (995)**

963 TCCTCTGGCCTCAAGGGCCTGGCCCCAGCTGAGATCTCTGCAGTGTGAAAAAGGAATTCAACATG

132 I L L G L K G L A P A E I S A V C E K G N F N M A

**NcoI (1035)**

BstBI (1103)

AsuII (1103)

1037 CATGGGCTGGCATGGTCATATTACATCGGATATCTCGGGCTGATCCCTGCCAGAGCTCCAGGCCGGATTGAAAC

157 H G L A W S Y Y I G Y L R L I L P E L Q A R I R T

1111 TTACAATCAGCATTACAACACCTGCTACGGGGTGCAGTGAGCCAGCGGCTGTATATTCTCCCTCCATTGGACT

181 Y N Q H Y N N L L R G A V S Q R L Y I L L P L D

**EcoRV (1064)**

**AgeI (1252)**

1185 GTGGGGTGCCTGATAACCTGAGTATGGCTGACCCCAACATTGCTTCCGGATAAACTGCCAGCAGACCGGT

206 C G V P D N L S M A D P N I R F L D K L P Q Q T G

1259 GACCGTGGCATCAAGGATCGGGTTACAGCAACAGCATCTATGAGCTCTGGAGAAGGGCAGCGGG

231 D R A G I K D R V Y S N S I Y E L L E N G Q R A G

1333 CACCTGTGCTGGAGTACGCCACCCCTGAGACTTGTGCAATGCAACATACAGTCAGCTGGCTTAA

255 T C V L E Y A T P L Q T L F A M S Q Y S Q A G F

1407 GCCGGGAGGATAGGCTTGAGCAGGCCAAACTCTTCTGCCGGACACTTGAGGACATCCTGGCAGATGCCCTGAG

280 S R E D R L E Q A K L F C R T L E D I L A D A P E

1481 TCTCAGAACAACTGCCGCCTCATTGCCTACCGAGAACCTGCAGATGACAGCAGCTTCTCGCTGTCCCAGGAGGT

305 S Q N N C R L I A Y Q E P A D D S S F S L S Q E V

1555 TCTCCGGCACCTGCGGAGGAAAAGGAAGAGGTTACTGTGGCAGCTGAAGACCTCAGCGGTGCCAGTA

329 L R H L R Q E E K E E V T V G S L K T S A V P S

1629 CCTCCACGATGTCCAAGAGCCTGAGCTCTCATCAGTGGAAAGGCCCTCCCTCCGCACGGATTTC

354 T S T M S Q E P E L L I S G M E K P L P L R T D F

**MscI (1745)**  
**NheI (1739)**

1703 TCTTGAGACCCAGGGTCACCAGGCCAGAGCCTCCAGTGTAGCTGGCCAGACATGATAAGATACTTGATGAGT  
379| S •

1777 TTGGACAAACCAACTAGAATGCAGTAAAAAAATGCTTATTGTGAAATTGTGATGCTATTGCTTATT

---

**HpaI (1877) MfeI (1888)**

1851 GTAACCATTATAAGCTGCAATAAACAAAGTTAACAAACAATTGCATTCTTATGTTCAGGTTAGGGGA

---

**EcoRI (1973)**

1925 GGTGTGGAGGTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGAATTCTAAATACAGCATAGCAA

1999 ACTTTAACCTCCAATCAAGCCTCTACTTGAATCCTTCTGAGGGATGAATAAGGCATAGGCATAGGGCTG

2073 TTGCCAATGTGCATTAGCTGTTGCAGCCTCACCTCTTCATGGAGTTAAGATATAGTGTATTTCCAAGG

---

**SspI (2212)**

2147 TTTGAACTAGCTCTCATTCTTATGTTAAATGCACTGACCTCCCACATTCCCTTTAGTAAATATTCA

Swal (2226)

2221 GAAATAATTAAATACATCATTGCAATGAAAATAATGTTTTATTAGGCAGAACATCCAGATGCTCAAGGCCCT

2295 TCATAATATCCCCAGTTAGTAGTTGGACTTAGGAAACAAAGGAACCTTAATAGAAATTGGACAGCAAGAAA

2369 GCGAGCTCTAGCTTCTGGTACTTGAGGGGATGAGTCCTCAATGGTGGTTTGACCGAGCTGCC

141| • N R T Y K L P I L E E I T T K V L K G

2443 ATTCACTCAATGAGCACAAAGCAGTCAGGAGCATAGTCAGAGATGAGCTCTGCACATGCCACAGGGCTGA

121| N M E I L V F C D P A Y D S I L E R C M G C P S V

**BstXI (2516)**

2517 CCACCTGATGGATCTGCCACCTCATCAGAGTAGGGTGCCTGACAGCCACAATGGTGTCAAAGTCCTCTGC

96| V R I S R D V E D S Y P H R V A V I T D F D K Q

**StuI (2651)**  
**Eco147I (2651)**

2591 CCGTTGCTCACAGCAGACCCAAATGGCAATGGCTTCAGCACAGACAGTGACCCCTGCCAATGTTAGGCCTCAATG

71| G N S V A S G I A I A E A C V T V R G I Y A E I H

2665 GACAGCAGAGATGATCTCCCAGTCTGGTCTGATGGCCGCCCCGACATGGTGTGCTTCATAGAGCA

47| V A S I I E G T K T R I A A G V H H K N D E Y L M

**BspHI (2801)**  
**XmnI (2793)**

2739 TGGTGATCTCTCACTGGCAGCTCCACCAAGCTCCAGATCCTGCTGAGAGATGTTGAAGGTCTTCATGATGGCC

22| T I K E T A V E V L E L D Q Q S I N F T K M ←

**VspI (2859)**  
**AseI (2859)**

2813 CTCCTATAGTGAGTCGTATTACTATGCCGATATACTATGCCGATGATTAATTGTCAAACAGCGTGGATGGC

2887 GTCTCCAGCTTATCTGACGGTCACTAACGAGCTCTGCTTATATAGACCTCCCACCGTACACGCCACCGCC

---

**SpeI (3014)**

2961 ATTTGCGTCAATGGGGCGGAGTTGTTACGACATTTGAAAGTCCCGTTGATTACTAGTCAAAACAAACTCC

3034 CATTGACGTCAATGGGGTGGAGACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCATTGATGTACTGC

---

**SnaBI (3142)**  
**Eco105I (3142)**

3108 CAAACCGCATCATGGTAATAGCGATGACTAATACGTAGATGACTGCCAAGTAGGAAAGTCCATAAGGT

---

**NdeI (3247)**

3182 CATGTACTGGCATAATGCCAGGCAGGCCATTACCGTCATTGACGTCAATAGGGGGCGTACTGGCATATGAT

3256 ACACTTGATGTAAGTGGCAGTTACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTATT

3330 GGCGTTACTATGGAACATACGTCAATTGACGTCAATGGGGGGGCGTGGGGCGTCAGCCAGGCGGGCC

**SdaI (3425) PacI (3433)**

3404 ATTTACCGTAAGTTATGTAACGCCCTGCAGGTTAA **TTAAGAACATGTGAGCAAAGGCCAGCAAAAGGCCAGG**  
  
3476 AACCGTAAAAGGCCGCGTTGGCGTTTCCATAGGCTCGCCCCCTGACGAGCATCACAAAATCGACG  
3550 CTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAGATACCAGGCCTTCCCTGGAGCTCCCTCGTGC  
3624 GCTCTCTGTTCCGACCCCTGCCGTTACCGATACTGTCCGCCCTTCTCCCTGGAGCGTGGCCTTCT

**ApaLI (3757)**

3698 CATAGCTCACGCTGTAGGTATCTCAGTCGGTAGGTCGTCGCTCCAAGCTGGCTGTGACGAACCCCC  
3772 CGTTCAGCCCGACCGCTGCGCTTATCCGTAACTATCGTCTGAGTCCAACCCGTAAGACACGACTTATCGC  
3846 CACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCCTGCTACAGAGTTCTGAAGTGG  
3920 TGGCCTAACTACGGCTACACTAGAAGAACAGTATTGGTATCTGCCTGCTGAAGCCAGTTACCTCGGAAA  
3994 AAGAGTTGGTAGCTCTGATCGGAAACAAACCACCGCTGGTAGCGGTGGTTTTGTTGCAAGCAGCAGA  
4068 TTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTGATCTTCTACGGGTCTGACGCTCAGTGGAACGAA

PacI (4173) SwaI (4182) **EagI (4193)**  
**NotI (4192)**

4142 AACTCACGTTAAGGGATTTGGTCATGGCTAGTTAATTAAACATTAAATC **AGCGGCCGCAATAAAATATCTTA**  
4216 TTTTCATTACATCTGTGTGGTTTTGTGAATCGTAACATACGCTCCATAAAACAAAACGAA  
4290 ACAAAACAAACTAGCAAATAGGCTGCCCCAGTGCAAGTGCAGGTGCCAGAACATTCTATCGAA